Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,338,040
  • Shares Outstanding, K 2,521,572
  • Annual Sales, $ 42,687 M
  • Annual Income, $ 14,066 M
  • 60-Month Beta 0.56
  • Price/Sales 2.94
  • Price/Cash Flow 10.36
  • Price/Book 1.72
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 22.34%
  • Historical Volatility 16.46%
  • IV Percentile 42%
  • IV Rank 33.58%
  • IV High 35.99% on 10/30/20
  • IV Low 15.45% on 05/24/21
  • Put/Call Vol Ratio 0.90
  • Today's Volume 110
  • Volume Avg (30-Day) 1,422
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 17,645
  • Open Int (30-Day) 13,024

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.18
  • Number of Estimates 3
  • High Estimate 1.20
  • Low Estimate 1.16
  • Prior Year 1.07
  • Growth Rate Est. (year over year) +10.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.55 +0.74%
on 09/20/21
52.74 -9.19%
on 09/02/21
-3.93 (-7.58%)
since 08/27/21
3-Month
47.55 +0.74%
on 09/20/21
53.27 -10.08%
on 08/20/21
-5.32 (-10.00%)
since 06/28/21
52-Week
44.76 +7.02%
on 10/30/20
54.26 -11.72%
on 06/14/21
-3.10 (-6.08%)
since 09/28/20

Most Recent Stories

More News
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids

FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.

REGN : 605.00 (-2.27%)
SNY : 47.90 (-0.46%)
NVS : 82.30 (-0.35%)
AMGN : 212.27 (-0.39%)
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis

Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.

REGN : 605.00 (-2.27%)
SNY : 47.90 (-0.46%)
INCY : 68.68 (-0.84%)
MOR : 12.15 (-1.78%)
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NASDAQ:...

KDMN : 8.80 (-0.45%)
SNY : 47.90 (-0.46%)
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

REGN : 605.00 (-2.27%)
SNY : 47.90 (-0.46%)
AZN : 57.63 (-1.86%)
GSK : 38.05 (-1.17%)
KADMON HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NasdaqGS: KDMN) to Sanofi...

KDMN : 8.80 (-0.45%)
SNY : 47.90 (-0.46%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Kadmon Holdings, Inc.

/PRNewswire/ --  is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. ("Kadmon Holdings" or the "Company") (NASDAQ: KDMN)...

KDMN : 8.80 (-0.45%)
SNY : 47.90 (-0.46%)
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.

SNY : 47.90 (-0.46%)
AZN : 57.63 (-1.86%)
PFE : 43.04 (-1.22%)
MRK : 73.32 (-0.05%)
LLY : 221.60 (-2.12%)
BAYRY : 13.7500 (-1.72%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company...

KDMN : 8.80 (-0.45%)
SNY : 47.90 (-0.46%)
KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Kadmon Holdings, Inc. (NASDAQ: KDMN) breached their...

KDMN : 8.80 (-0.45%)
SNY : 47.90 (-0.46%)
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study

Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.

REGN : 605.00 (-2.27%)
SNY : 47.90 (-0.46%)
TBIO : 37.36 (-0.13%)
KDMN : 8.80 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

3rd Resistance Point 48.74
2nd Resistance Point 48.48
1st Resistance Point 48.19
Last Price 47.90
1st Support Level 47.64
2nd Support Level 47.38
3rd Support Level 47.09

See More

52-Week High 54.26
Fibonacci 61.8% 50.63
Fibonacci 50% 49.51
Fibonacci 38.2% 48.39
Last Price 47.90
52-Week Low 44.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar